CM
GNMK

Crestline Management’s GenMark Diagnostics, Inc GNMK Stock Holding History

Crestline Management’s Portfolio GNMK Stock Details GNMK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-36,046
Closed -$426K – 188
2017
Q2 		$426K Buy
+36,046
New +$461K 0.06% 116

Other funds holding GNMK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Crestline Management's GNMK Position: Q3 2017 in Review

Crestline Management sold out of GenMark Diagnostics, Inc (GNMK) in Q3 2017, closing a stake of 36,046 shares — an estimated $426K sold.

Crestline Management first reported a position in GNMK in Q2 2017 and held it in 1 quarter. The position peaked at $426K in Q2 2017. 96 funds tracked by Wall St. Rank hold GNMK as of Q3 2017.

  • Crestline Management reported no remaining GenMark Diagnostics, Inc position as of Q3 2017 after selling out during the quarter.
  • Crestline Management sold 36,046 GenMark Diagnostics, Inc shares in Q3 2017, an estimated $426K.
  • Crestline Management first reported a position in GenMark Diagnostics, Inc in Q2 2017 and held it in 1 quarter.
  • Crestline Management's GenMark Diagnostics, Inc position peaked at $426K in Q2 2017.
  • 96 funds tracked by Wall St. Rank held GenMark Diagnostics, Inc as of Q3 2017.

Based on Crestline Management's 13F filing for Q3 2017, filed 14 Nov 2017.